抗血友病因子薬の世界市場規模：製品別、用途別、地域別、範囲および予測

抗血友病因子薬の市場規模および予測

抗血友病因子薬の市場規模は、ここ数年大幅な成長率で急成長しており、市場推計・予測期間（2021～2028年）には大幅な成長が見込まれます。

抗血友病因子薬は、出血性疾患の患者における重度の出血発作の治療と制御に使用されます。人々の間で意識が高まり、世界中の人々の間で希少疾患が増加していることは、ヘルスケア分野にとって重要な問題であり、これが抗血友病因子薬市場の成長を促進する要因となっています。世界の抗血友病因子薬市場レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界の抗血友病因子薬市場の定義

抗血友病因子薬は、血液凝固第VIII因子（血友病A）の濃度が低い患者における出血エピソードの抑制と予防に使用されます。また、手術前に出血を止めるためにも使用されます。血液凝固第VIII因子の濃度が正常な人は、抗血友病因子としても知られる体内の血液凝固第VIII因子の出血により、傷害、手術後の出血、および血液凝固第VIII因子の出血のリスクが高まります。この製剤は、失われた第VIII因子を一時的に補充します。通常、血液凝固や止血を助けるタンパク質が存在します。この薬は通常、静脈注射で少なくとも5～10分間、または医師の指示に従って投与されます。投与量や患者の反応によっては、時間をかけてゆっくりと投与する必要があります。

世界の抗血友病因子薬の市場概要

市場成長を促進する主な要因は、人々の間で希少疾患の症例数が増加していることです。この医薬品は、血液凝固第VIII因子（血友病A）の濃度が低い患者における出血エピソードの抑制と予防に使用されます。また、これらの患者では手術前に出血を止めるために使用されます。一般的な血液凝固第VIII因子レベルの人は、傷害/手術後や内出血のリスクが高くなります。この製品には、抗血友病因子としても知られるヒト血液凝固第VIII因子が含まれています。この製品は、失われた第VIII因子と血液中に通常存在するタンパク質を一時的に補い、血栓や止血を助けます。人口の間でこのような希少疾患に対する認識が高まり、これらの生命を脅かす疾患の予防と管理に政府が関与していることが、抗血友病薬市場の推定成長の主な要因となっています。加えて、主要製薬企業による血友病の新規治療法の研究開発への投資の増加が、市場の急拡大を牽引しています。

このリスクを軽減するために、献血者の慎重なスクリーニング、独自の製造工程、多くの検査が行われているが、この薬剤による感染リスクはわずかであり、抗血友病因子薬市場の成長を制限しています。

目次

第1章 世界の抗血友病因子薬市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 抗血友病因子薬の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 抗血友病因子薬の世界市場：製品別

• 概要
• 250 IU
• 500 IU
• 1000 IU
• 1500 IU
• 2000 IU
• 3000 IU
• 4000 IU
• その他

第6章 抗血友病因子薬の世界市場：用途別

• 概要
• 成人
• 小児

第7章 抗血友病因子薬の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の抗血友病因子薬市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Bayer
• Shire
• Novo Nordisk
• Pfizer
• Grifols
• CSL Behring
• Sanofi
• Cigna
• Octapharma
• GC Pharma

第10章 関連レポート関連レポート

Antihemophilic Factor Drug Market Size and Forecast

Antihemophilic Factor Drug Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Antihemophilic factor drug is used to treat and control severe bleeding spells in patients with a bleeding problem. Increasing awareness among people and growing rare disorders among people across the globe is a significant problem for the healthcare field is the factor driving the market growth of the Antihemophilic Factor Drug Market. The Global Antihemophilic Factor Drug Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Antihemophilic Factor Drug Market Definition

Anti-hemophilia factor drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to stop bleeding. People with normal factor VIII levels are at increased risk of injury, post-surgery bleeding, and factor VIII bleeding in the body, also known as an anti-hemophilia factor. This product temporarily replaces lost factor VIII. A protein is usually present to help blood clots and stop bleeding. The medicine is usually given by intravenous injection for at least 5-10 minutes or as directed by the doctor. Depending on your dose and patient response, the drug may need to be given more slowly over time. After receiving this medicine for the first time at a hemophilia treatment center or hospital, some patients can self-administer this medicine at home. The drugs and solutions used for mixing were refrigerated. After adding the resolution to the powder, some brands of this drug may need to shake the vial for 10-15 seconds before gently rotating the vial to dissolve the powder completely. Ask your pharmacist about the correct combination of the medicines. Visually inspect for particulate matter or discoloration before using this product.

Global Antihemophilic Factor Drug Market Overview

The primary factor driving the market growth is the increasing number of rare disorder cases among people is the factor driving the market growth. This drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to stop bleeding. People at the general factor VIII level are at increased risk of injury / post-surgery and internal bleeding. This product contains Human Factor VIII, also known as an anti-hemophilia factor. This product temporarily replaces lost element VIII and a protein usually present in the blood to help blood clots and stop bleeding. Increasing awareness of such rare diseases among the population and government involvement in preventing and managing these life-threatening diseases are key factors behind the estimated growth of the antihemophilic drug market. In addition, increased investment by leading pharmaceutical companies in the research and development of new treatments for hemophilia is driving market expansion at an alarming rate.

Careful screening of blood donors, a unique manufacturing process, and many tests have been used to reduce this risk, but the risk of infection with this drug is minimal, limiting the market growth of the Antihemophilic factor Drug Market.

Global Antihemophilic Factor Drug Market: Segmentation Analysis

The Global Antihemophilic Factor Drug Market is segmented on the basis of Product, Application, and Geography.

Antihemophilic Factor Drug Market by Product

• 250 IU
• 500 IU
• 1000 IU
• 1500 IU
• 2000 IU
• 3000 IU
• 4000 IU
• Other potencies

Based on Product, the market is segmented into 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU, 3000 IU, 4000 IU and Other potencies.

Antihemophilic Factor Drug Market by Application

• Adult
• Pediatric

Based on the Application, the Adult segment holds a large number of shares in the market because the low risk for hypersensitivity reactions increases cases of disorders in adult ages peoples, which is the factor that boosts the market growth of the Antihemophilic factor Drug Market.

Antihemophilic Factor Drug Market by Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the North American region holds a large number of shares in the market because of the increasing number of cases in the region. The existence of key players in the region is the factor that propels the market growth of the Antihemophilic factor Drug Market.

Key Players

The "Global Antihemophilic Factor Drug Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are

Bayer, Shire, Novo Nordisk, Pfizer, Grifols, CSL Behring, Sanofi, Cigna, Octapharma, and GC Pharma.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 250 IU
• 5.3 500 IU
• 5.4 1000 IU
• 5.5 1500 IU
• 5.6 2000 IU
• 5.7 3000 IU
• 5.8 4000 IU
• 5.9 Other potencies

6 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Adult
• 6.3 Pediatric

7 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Bayer
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Shire
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Novo Nordisk
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Pfizer
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Grifols
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 CSL Behring
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Development
• 9.7 Sanofi
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Cigna
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Octapharma
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Development
• 9.10 GC Pharma
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Development

10 Related Reports